How We Do It®: Novel Biologic Strategies Reshaping Treatment Decision-Making in Pediatric to Adult Hodgkin Lymphoma

September 8, 2023

Countdown to Event

00

Days

00

Hours

00

Mins

00

Secs

Overview:

With the development of antibody-drug conjugates and immune checkpoint inhibitors, the treatment of both adult and pediatric patients with advanced Hodgkin lymphoma (HL) is undergoing a transformation. New therapeutic targets are also emerging for patients with relapsed/refractory disease. Thus, there is a need for education regarding current and emerging novel therapeutic approaches in the management of HL.

This How We Do It® symposium will bring together clinical experts in lymphoma to highlight evolving approaches to the diagnosis and treatment of patients with HL. Evidence-based assessments of current standards of practice and the most important clinical trials will set the stage for extensive case-based discussion sessions, which will address newly diagnosed patients, relapsed/refractory disease, and pediatric patients. Additionally, strategies to maximize the safety of treatment regimens in patients with HL will be evaluated.

Learning Objectives:

Upon completion of this activity, participants will be able to:

  • Develop personalized care plans for patients with HL based on patient-related factors, risk stratification and treatment history
  • Explain the efficacy and safety of evolving adult and pediatric strategies for advanced HL from clinical trials, including real world evidence in multiple lines of care
  • Apply proactive strategies to recognize and manage adverse events associated with the use of novel therapies for the management of adult and pediatric patients with advanced HL
  • Utilize evidence to develop case-based strategies for the management of adult and pediatric patients with HL

Program Chair:

Joseph M. Connors, MD, CM

To view full profile, click on the Program Chair tab above.